FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366998632> ?p ?o ?g. }

• W4366998632 endingPage "52" @default.
• W4366998632 startingPage "43" @default.
• W4366998632 abstract "Immune checkpoint inhibitors (ICIs) including anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies have been increasingly used for various malignancies. These ICIs activate immune functions to treat malignant tumors; however, this causes characteristic complications called immune-related adverse events (irAE). In the gastrointestinal tract, ICIs cause adverse events such as diarrhea and enterocolitis, thus warranting treatment discontinuation. These irAEs require treatment that suppresses immunity; however, no treatment strategies based on approved guidelines have been reported. This review aimed to investigate the current treatment status for refractory cases of ICI-induced colitis in accordance with their diagnosis, therapy, and prognosis.We systematically reviewed studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) checklist. Two investigators searched PubMed and Scopus in January 2019. We extracted data, including the number of ICI-treated patients developing colitis and diarrhea. The number of cases classified as severe per the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) definitions and the progress of corticosteroid-treated and anti-TNF-α- antibody-treated cases (e.g., infliximab) were recorded. Details of further treatment were also recorded for cases that did not improve with antiTNF-α- antibody. Among patients receiving anti-CTLA-4 antibody, corticosteroids were administered to 14.6% of patients, and infliximab was administered to 5.7% of patients. Among patients receiving anti-PD-1/PD-L1 antibody, corticosteroids were administered to 2.37% of patients. For refractory cases unsuccessful with infliximab, the continuation of infliximab every 2 weeks, tacrolimus administration, prolonged corticosteroid treatment, colectomy, or vedolizumab administration were reported.Treatment of ICI-induced colitis is important to avoid the need to discontinue cancer treatment. Many therapeutic agents for inflammatory bowel disease are reportedly effective in treating refractory ICI-induced colitis." @default.
• W4366998632 created "2023-04-27" @default.
• W4366998632 creator A5013194037 @default.
• W4366998632 creator A5033292690 @default.
• W4366998632 creator A5065128587 @default.
• W4366998632 creator A5085144733 @default.
• W4366998632 creator A5087888150 @default.
• W4366998632 date "2021-06-30" @default.
• W4366998632 modified "2023-09-26" @default.
• W4366998632 title "Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review" @default.
• W4366998632 cites W1556990476 @default.
• W4366998632 cites W1605315445 @default.
• W4366998632 cites W1987925515 @default.
• W4366998632 cites W1995245022 @default.
• W4366998632 cites W2006091295 @default.
• W4366998632 cites W2034392291 @default.
• W4366998632 cites W2050886412 @default.
• W4366998632 cites W2067545345 @default.
• W4366998632 cites W2068834940 @default.
• W4366998632 cites W2099092516 @default.
• W4366998632 cites W2104750134 @default.
• W4366998632 cites W2107328434 @default.
• W4366998632 cites W2109653150 @default.
• W4366998632 cites W2119198740 @default.
• W4366998632 cites W2128035403 @default.
• W4366998632 cites W2154391127 @default.
• W4366998632 cites W2165456770 @default.
• W4366998632 cites W2166662937 @default.
• W4366998632 cites W2169912308 @default.
• W4366998632 cites W2338994579 @default.
• W4366998632 cites W2515115657 @default.
• W4366998632 cites W2567564314 @default.
• W4366998632 cites W2588366403 @default.
• W4366998632 cites W2601055810 @default.
• W4366998632 cites W2604253421 @default.
• W4366998632 cites W2607166620 @default.
• W4366998632 cites W2619461121 @default.
• W4366998632 cites W2745624257 @default.
• W4366998632 cites W2747107882 @default.
• W4366998632 cites W2754843476 @default.
• W4366998632 cites W2759963646 @default.
• W4366998632 cites W2761087768 @default.
• W4366998632 cites W2771433910 @default.
• W4366998632 cites W2778022170 @default.
• W4366998632 cites W2783137027 @default.
• W4366998632 cites W2786816161 @default.
• W4366998632 cites W2789502254 @default.
• W4366998632 cites W2790066065 @default.
• W4366998632 cites W2794510318 @default.
• W4366998632 cites W2795629103 @default.
• W4366998632 cites W2800213865 @default.
• W4366998632 cites W2885781276 @default.
• W4366998632 cites W2889257598 @default.
• W4366998632 cites W2897516580 @default.
• W4366998632 cites W2898631010 @default.
• W4366998632 cites W2903072327 @default.
• W4366998632 cites W2907056240 @default.
• W4366998632 cites W2913054974 @default.
• W4366998632 cites W2999042597 @default.
• W4366998632 cites W4256460627 @default.
• W4366998632 doi "https://doi.org/10.2739/kurumemedj.ms682006" @default.
• W4366998632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37100606" @default.
• W4366998632 hasPublicationYear "2021" @default.
• W4366998632 type Work @default.
• W4366998632 citedByCount "1" @default.
• W4366998632 countsByYear W43669986322023 @default.
• W4366998632 crossrefType "journal-article" @default.
• W4366998632 hasAuthorship W4366998632A5013194037 @default.
• W4366998632 hasAuthorship W4366998632A5033292690 @default.
• W4366998632 hasAuthorship W4366998632A5065128587 @default.
• W4366998632 hasAuthorship W4366998632A5085144733 @default.
• W4366998632 hasAuthorship W4366998632A5087888150 @default.
• W4366998632 hasBestOaLocation W43669986321 @default.
• W4366998632 hasConcept C121608353 @default.
• W4366998632 hasConcept C126322002 @default.
• W4366998632 hasConcept C17991360 @default.
• W4366998632 hasConcept C197934379 @default.
• W4366998632 hasConcept C203014093 @default.
• W4366998632 hasConcept C2775862500 @default.
• W4366998632 hasConcept C2776258884 @default.
• W4366998632 hasConcept C2777138892 @default.
• W4366998632 hasConcept C2777701055 @default.
• W4366998632 hasConcept C2777793932 @default.
• W4366998632 hasConcept C2778715236 @default.
• W4366998632 hasConcept C2779802037 @default.
• W4366998632 hasConcept C2780057760 @default.
• W4366998632 hasConcept C71924100 @default.
• W4366998632 hasConcept C90924648 @default.
• W4366998632 hasConceptScore W4366998632C121608353 @default.
• W4366998632 hasConceptScore W4366998632C126322002 @default.
• W4366998632 hasConceptScore W4366998632C17991360 @default.
• W4366998632 hasConceptScore W4366998632C197934379 @default.
• W4366998632 hasConceptScore W4366998632C203014093 @default.
• W4366998632 hasConceptScore W4366998632C2775862500 @default.
• W4366998632 hasConceptScore W4366998632C2776258884 @default.
• W4366998632 hasConceptScore W4366998632C2777138892 @default.
• W4366998632 hasConceptScore W4366998632C2777701055 @default.
• W4366998632 hasConceptScore W4366998632C2777793932 @default.

• next